Goal Dose of Lantus for This Patient
Start with 10 units of Lantus once daily at the same time each day, then titrate upward every 3 days based on fasting blood glucose until reaching target FBG <100 mg/dL (5.5 mmol/L). 1
Initial Dosing Strategy
For this 115-lb (52-kg) patient with type 2 diabetes and A1c of 11% who is insulin-naïve, the FDA-approved starting dose is:
- 10 units once daily (or alternatively 0.2 units/kg = ~10 units for this patient) 1
- Administer at the same time every day, subcutaneously 1
This conservative starting dose is appropriate despite the markedly elevated A1c of 11%, as it minimizes hypoglycemia risk while establishing baseline insulin requirements.
Titration Algorithm
Use patient-managed titration for faster A1c reduction:
- Increase dose by 2 units every 3 days if fasting blood glucose remains above target
- Hold increases if blood glucose drops below 72 mg/dL (4.0 mmol/L) 2
- Target fasting blood glucose: <100 mg/dL (<5.5 mmol/L) 3, 2
The AT.LANTUS trial demonstrated that patient-managed titration (increasing 2 units every 3 days) achieved greater A1c reductions (-1.22%) compared to clinic-managed titration (-1.08%), though with slightly higher hypoglycemia rates (33.3% vs 29.8%) 2. Given this patient's very high A1c of 11%, the more aggressive patient-managed approach is warranted.
Expected Final Dose Range
Based on pooled trial data, most patients with type 2 diabetes reach therapeutic doses of:
- Average: 38-52 units daily at 24 weeks 4
- Typical range: 0.5-1.0 units/kg (26-52 units for this 52-kg patient) 5
Important caveat: If the dose exceeds 0.5 units/kg (~26 units) without achieving adequate glycemic control, consider adding prandial insulin rather than continuing to escalate basal insulin alone 5. Doses above 0.5 units/kg often indicate "overbasalization"—using excessive basal insulin to compensate for inadequate postprandial coverage, which leads to weight gain without proportional A1c improvement 3, 5.
Clinical Signals to Add Prandial Insulin
Watch for these indicators that basal insulin alone is insufficient:
- Bedtime-to-morning glucose differential ≥50 mg/dL (2.8 mmol/L)
- Fasting glucose at target but A1c remains >7%
- Significant postprandial hyperglycemia
- Basal dose exceeding 0.5 units/kg 3
When this occurs, add 4 units of rapid-acting insulin before the largest meal (or 10% of basal dose), rather than continuing to increase Lantus 3.
Why GLP-1 RA Discontinuation Matters
Since this patient can no longer use GLP-1 RA therapy, they lose the weight-neutral and hypoglycemia-protective benefits of that drug class. This makes careful insulin titration even more critical to avoid excessive weight gain. The 2025 ADA guidelines emphasize that when A1c is >10% (as in this case with 11%), insulin is appropriate as first injectable therapy 3.